Discodermolide Biosynthesis Genes

Information

  • Research Project
  • 6549229
  • ApplicationId
    6549229
  • Core Project Number
    R43CA097889
  • Full Project Number
    1R43CA097889-01
  • Serial Number
    97889
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/1/2002 - 22 years ago
  • Project End Date
    6/30/2004 - 20 years ago
  • Program Officer Name
    FU, YALI
  • Budget Start Date
    7/1/2002 - 22 years ago
  • Budget End Date
    6/30/2004 - 20 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
  • Award Notice Date
    6/24/2002 - 22 years ago
Organizations

Discodermolide Biosynthesis Genes

DESCRIPTION (provided by applicant): The long-range goal of our research is to develop an economical method for producing the experimental anti-tumor drug, (+) -discodermolide, by microbiological fermentation. Pre-clinical investigation of discodermolide has been hampered by inadequate supply of this marine polyketide. It currently is available by isolation or total synthesis, but the cost of the drug is very high. To enable development of a fermentation based process, the discodermolide biosynthetic genes will be cloned from the marine sponge from which discodermolide is isolated, followed by expression of these genes in a bacterial host. The immediate goal of Phase I research is to identify and clone many of the discodermolide biosynthesis genes by pursuing the following specific aims: (1) Detect modular polyketide synthase (PKS) and carbamoyl phosphate transferase (CPT) gene homologs by PCR analysis of cells or cell extracts of the marine sponge that produces discodermolide. (2) Prepare a fosmid library using DNA isolated from the sponge or its putative microbial symbiont and by PCR analysis identify clones that contain these PKS and CPT genes. (3) Sequence the PKS and CPT genes to the extent required to justify their involvement in discodermolide biosynthesis. Our research will also establish the technological base for a general approach to making many other currently scarce marine polyketides with anti-tumor activity available in large amounts for drug development.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100005
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:100005\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    KOSAN BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
    932981319
  • Organization City
    HAYWARD
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94545
  • Organization District
    UNITED STATES